HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioXcel Therapeutics (BTAI) Investors with Substantial Losses to Contact Firm’...
SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period: Dec. 15, 2021 – June 28, 2023 Lead Plaintiff Deadline: …